Carvedilol phosphate hemihydrate

• CAT Number: I004301
• CAS Number: 610309-89-2
• Molecular Formula: C24H26N2O4 . H3PO4 .1/2H2O
• Molecular Weight: 513.48
• Purity: ≥95%
• Target: Neuronal Signaling
• Solubility: 10 mM in H2O
• Storage: -20°C
• IC50: 3.8 μM ( inhibition of LDL oxidation)
• IUPAC Name: 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol;phosphoric acid;hydrate
• InChI: InChI=1S/2C24H26N2O4.2H3O4P.H2O/c2*1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;2*1-5(2,3)4;/h2*2-12,17,25-27H,13-16H2,1H3;2*(H3,1,2,3,4);1H2
• InChIKey: LHNYXTULDSJZRB-UHFFFAOYSA-N
• SMILES: COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O.O.OP(=O)(O)O.OP(=O)(O)O

Carvedilol Phosphate Hemihydrate（Cat No.:I004301）is a non-selective beta-adrenergic blocker with alpha-1 blocking activity, used primarily in the treatment of hypertension and heart failure. By blocking beta receptors, it reduces heart rate and myocardial oxygen demand, while its alpha-1 blocking properties promote vasodilation, lowering blood pressure. Carvedilol also has antioxidant properties, offering additional cardiovascular protection. Its dual mechanism makes it effective in improving heart function and reducing symptoms in patients with chronic heart failure, as well as preventing heart attacks in individuals with high blood pressure or heart disease.

Reference

[1]. Chen J, et al. The effects of carvedilol on cardiac structural remodeling: The role of endogenous nitric oxide in the activity of carvedilol. Mol Med Rep. 2013 Apr;7(4):1155-1158.
[2]. Stafylas PC, et al. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23-30.
[3]. Othman AA, et al. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J. 2007 Jun 15;9(2):E208-18.
[4]. Koshimizu TA, et al. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-672.